Journal of Cancer Research and Clinical Oncology最新文献

{"title":"Correction: Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma.","authors":"Guichun Huang, Longbang Chen","doi":"10.1007/s00432-025-06103-2","DOIUrl":"10.1007/s00432-025-06103-2","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"108"},"PeriodicalIF":2.7,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11903533/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143615620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic lymphocytic leukemia (CLL) screening and abnormality detection based on multi-layer fluorescence imaging signal enhancement and compensation.","authors":"Lemin Shi, Ping Gong, Mingye Li, Dianxin Song, Hao Zhang, Zhe Wang, Xin Feng","doi":"10.1007/s00432-025-06150-9","DOIUrl":"10.1007/s00432-025-06150-9","url":null,"abstract":"<p><strong>Purpose: </strong>Fluorescence in situ hybridization (FISH) plays a critical role in cancer screening but faces challenges in signal clarity and manual intervention. This study aims to enhance FISH signal clarity, improve screening efficiency, and reduce false negatives through an automated image acquisition and signal enhancement framework.</p><p><strong>Methods: </strong>An automated workflow was developed, integrating a dynamic signal enhancement method that optimizes global and local features. An improved Cycle-GAN network was introduced, incorporating residual connections and layer-wise supervision to accurately model and compensate for complex signal characteristics. Key metrics such as signal brightness, edge gradients, contrast improvement index (CII), and structural similarity index (SSIM) were used to evaluate performance.</p><p><strong>Results: </strong>The proposed method increased weak signal brightness by 49.02%, edge gradients by 48.61%, and CII by 32.52%. The SSIM reached 0.996, indicating high fidelity to original signals.</p><p><strong>Conclusion: </strong>Visual analysis demonstrated clearer, more continuous, and uniform fluorescence signals, effectively mitigating fragmentation and uneven distribution. These improvements reduced false negatives and enhanced genomic abnormality detection accuracy. The proposed method significantly improves FISH signal clarity and stability, providing reliable support for cancer screening, genomic abnormality detection, molecular typing, prognosis evaluation, and targeted treatment planning.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"106"},"PeriodicalIF":2.7,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone mineral density as potential individual prognostic biomarker in patients with neurosurgically treated spinal metastasis.","authors":"H Asoglu, T Lampmann, M Jaber, L Khalafov, J Dittmer, I Ilic, G H Gielen, M Toma, H Vatter, Z Bendella, M Schneider, C Schmeel, M Hamed, M Banat","doi":"10.1007/s00432-025-06142-9","DOIUrl":"10.1007/s00432-025-06142-9","url":null,"abstract":"<p><strong>Introduction: </strong>Bone mineral density (BMD) plays a crucial role in diagnosing and treating various systemic chronic diseases. Patients with multiple or singular spinal metastasis (SM) are typically in advanced stages of systemic cancer, often leading to significant alterations in BMD. The present study investigated the prognostic value of perioperative Hounsfield units (HU) as a surrogate independent marker for estimated BMD in patients with SM after surgical treatment (ST).</p><p><strong>Methods: </strong>HU values, serving as a surrogate for estimated BMD, were measured from circular regions of interest (ROIs) in the spine -first lumbar vertebra (L1)- from routine preoperative staging computed tomography (CT) scans in 187 patients after ST. The estimated BMD was stratified into pathologic and physiologic values and correlated with survival parameters in our cohorts.</p><p><strong>Results: </strong>Median L1 BMD of 92 patients (49%) with pathologic BMD was 79.5 HU (IQR 67.25-93.5) compared to 145 HU (IQR 123-166) for 95 patients (51%) with physiologic BMD (p ≤ 0.001). Patients with pathological BMD exhibited a median overall survival of 8 months compared to 12.2 months in patients with physiologic BMD (p = 0.006). Multivariable analysis revealed pathologic BMD as an independent negative prognostic predictor for increased 1 year mortality (AUC: 0.637, 95% CI: 0.556-0.718; p = 0.001).</p><p><strong>Conclusions: </strong>The present study demonstrates that decreased perioperative BMD values, as derived from HU measurements, may represent a previously unrecognized negative prognostic factor in patients of SM after ST. The estimated perioperative BMD could emerge as an individualized, readily available potential biomarker for prognostic, treatment, and discussion of affected patients with SM.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"105"},"PeriodicalIF":2.7,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11893684/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143597005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of LIMK1 as a biomarker in clear cell renal cell carcinoma: from data mining to validation.","authors":"Yifei Li, Congcong Fan, Feng Jiang, Jingnan Zhang, Yanzhen Li, Yanjie Jiang, Rui Zhang, Zhixian Yu, Siqi Wang","doi":"10.1007/s00432-025-06146-5","DOIUrl":"10.1007/s00432-025-06146-5","url":null,"abstract":"<p><strong>Purpose: </strong>Clear cell renal cell carcinoma (ccRCC) is one of the most common types of renal cancer. LIM kinase 1 (LIMK1) reportedly plays an important role in tumorigenesis. However, the involvement of LIMK1 in the progression of ccRCC remains ambiguous.</p><p><strong>Methods: </strong>Based on the TCGA and CPTAC databases, the expression of LIMK1 in ccRCC was evaluated. In the TCGA-ccRCC cohort, the relationships between LIMK1 and immune cell infiltration as well as immune checkpoints were assessed. The high expression of LIMK1 in ccRCC was verified by qRT-PCR in four RCC cell lines. Immunohistochemistry was used to evaluate the expression of LIMK1 in clinical samples. The association between LIMK1 expression and survival prognosis was explored via Kaplan-Meier survival curve in the TCGA-ccRCC and local cohorts. The effects of LIMK1 knockdown on the proliferation, migration, and invasion abilities of RCC cells were evaluated via colony, CCK-8, wound healing, and Transwell assays.</p><p><strong>Results: </strong>Elevated expression level of LIMK1 was found in the TCGA-ccRCC cohort and was confirmed in RCC cell lines and clinical samples. Up-regulation of LIMK1 was found to be correlated with poor prognosis in TCGA-ccRCC and external cohorts. In addition, high-LIMK1 was associated with clinicopathological stage, immune cell infiltration and immune checkpoint in ccRCC. Importantly, knockdown of LIMK1 diminished the capability of proliferation, migration, and invasion in RCC cells.</p><p><strong>Conclusion: </strong>LIMK1 may serve as a promising diagnostic and prognostic biomarker of ccRCC.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"104"},"PeriodicalIF":2.7,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11890329/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143582286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Semaglutide, a glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway.","authors":"Can Wang, Zhengzheng Wu, Jiaying Zhou, Bin Cheng, Yulei Huang","doi":"10.1007/s00432-025-06154-5","DOIUrl":"10.1007/s00432-025-06154-5","url":null,"abstract":"<p><strong>Aims: </strong>Researches have shown that diabetes mellitus (DM) can promote the risk and progression of oral squamous cell carcinoma (OSCC). Semaglutide, a glucagon-like peptide-1 receptor agonist, is currently employed to treat type 2 diabetes mellitus (T2DM) and obesity. This study intends to explore the potential effects and mechanism of Semaglutide on OSCC.</p><p><strong>Methods: </strong>The expression of GLP-1R in OSCC cells and tissues was evaluated by qRT-PCR, western blot and immunohistochemistry assays. Cell proliferation, invasion, migration and apoptosis abilities were determined by relevant experiments. Western blot was employed to verify the expression of relevant proteins and examine the effect of Semaglutide on the MAPK signaling pathway. The xenograft transplantation model of OSCC was established to examine the anti-cancer effects of Semaglutide in vivo and immunohistochemistry assays were performed on tumor tissues.</p><p><strong>Results: </strong>GLP-1R expression was elevated in OSCC cells and tissues as compared with that in normal. Semaglutide effectively inhibited the proliferation, migration and invasion of OSCC cells while concurrently promoting apoptosis. Moreover, Semaglutide specifically activated the P38 MAPK signaling pathway without significant influence on ERK1/2 or SAPK/JNK, and its pro-apoptotic effects in OSCC cells was related to P38 pathway activation. Animal experiments verified the inhibitory effect of Semaglutide on OSCC tumors in mice.</p><p><strong>Conclusions: </strong>Semaglutide exerts inhibitory actions on OSCC and may induce apoptosis in OSCC cells via the P38 MAPK signaling pathway. This study has significant implications for the treatment of patients with diabetes who are also afflicted by OSCC.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"103"},"PeriodicalIF":2.7,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11889073/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of interdisciplinary tumor boards (ITB) and personalized treatment on survival outcomes in metastatic castration-resistant prostate cancer.","authors":"Laura Lawaczeck, Anna Rüdiger, Jörg Hennenlotter, Joël Hammes, Valentina Spingler, Simon Walz, Eva Erne, Igor Tsaur, Steffen Rausch","doi":"10.1007/s00432-025-06135-8","DOIUrl":"10.1007/s00432-025-06135-8","url":null,"abstract":"<p><strong>Purpose: </strong>Interdisciplinary tumor boards (ITB) are essential in optimizing treatment recommendations for metastatic castration-resistant prostate cancer (mCRPC) by incorporating oncology guidelines, clinical trials, and patient-specific factors to ensure individualized care. This study examines clinical parameters that influence ITB recommendations, evaluates their adherence to guidelines, and assesses their impact on patient survival.</p><p><strong>Methods: </strong>In a retrospective analysis, data from 187 mCRPC patients discussed at an ITB in a tertiary care center in 2018 were evaluated. Patient- and disease-specific factors were correlated with adherence to National Comprehensive Cancer Network^® (NCCN^®) guidelines and overall survival (OS). The impact of clinical parameters on survival outcomes was assessed through univariate and multivariate analyses.</p><p><strong>Results: </strong>The median patient age was 72.8 years, with a median prostate-specific antigen (PSA) level of 65.0 ng/ml. Guideline-compliant recommendations were given in 42.9% of cases, while 57.1% received individualized recommendations. Clinical trial eligibility was noted in 24.8% of patients. Individualized ITB recommendations were associated with significantly longer OS (38.3 vs. 21.2 months, p = 0.03). Shorter OS correlated with renal impairment (p = 0.007), symptomatic metastases (p < 0.0001), and visceral metastases (p < 0.0001). Limitations include the retrospective design, lack of follow-up on therapy adherence, and absence of progression-free survival (PFS) data.</p><p><strong>Conclusion: </strong>ITB discussions improve survival in mCRPC patients, mainly due to personalized approaches and better access to clinical trials. Visceral and symptomatic metastases as well as renal impairment are risk factors for reduced OS, emphasizing the need for careful management of these high-risk patients. The results support the expanded use of ITB to improve mCRPC treatment outcomes.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"101"},"PeriodicalIF":2.7,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11885382/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The screening value of mammography for breast cancer: an overview of 28 systematic reviews with evidence mapping.","authors":"Jiyuan Shi, Jiang Li, Ya Gao, Wanqing Chen, Liang Zhao, Ni Li, Jinhui Tian, Zheng Li","doi":"10.1007/s00432-025-06122-z","DOIUrl":"10.1007/s00432-025-06122-z","url":null,"abstract":"<p><strong>Background: </strong>The effectiveness of mammography screening in reducing breast cancer mortality and the accuracy of various mammography techniques have been widely studied. However, the quality and findings of existing systematic reviews and meta-analyses require comprehensive evaluation.</p><p><strong>Methods: </strong>A systematic literature search was conducted in the Cochrane Library, EMBASE, and PubMed for systematic reviews published up until December 20, 2022. A total of 28 systematic reviews with meta-analyses were included. Two reviewers independently extracted data and assessed methodological quality using the Risk Of Bias In Systematic Reviews (ROBIS) tool.</p><p><strong>Results: </strong>Of the 28 systematic reviews included, only 17.9% were rated as low risk of bias. The pooled estimates for breast cancer mortality reduction due to mammography screening ranged from 0.51 (95% CI 0.46-0.55) to 1.04 (95% CI 0.84-1.27). The results were influenced by study design, age, and follow-up duration, with an overall trend indicating that mammography screening reduces breast cancer mortality. Sensitivity of mammography techniques ranged from 55 to 91%, and specificity from 84 to 97%. Digital breast tomosynthesis combined with synthetic contrast-enhanced spectral mammography, digital mammography, and film mammography demonstrated relatively high cancer detection rates and low false positives.</p><p><strong>Conclusion: </strong>Mammography screening appears effective in reducing breast cancer mortality. The accuracy of various mammography techniques is generally reliable, with certain combinations showing high detection rates. However, the methodological quality of most included reviews was at high risk of bias, indicating a need for higher-quality studies in the future.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"102"},"PeriodicalIF":2.7,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11885354/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world treatment patterns and clinical outcomes in patients with locally advanced or metastatic urothelial carcinoma in Germany: retrospective CONVINCE study.","authors":"Katrin Schlack, Stefan Machtens, Thomas Kubin, Markus Ruhnke, Clemens Schulte, Anna Eisen, Ulrike Osowski, Silke Guenther, Mairead Kearney, Rainer Lipp, Stephan Schmitz","doi":"10.1007/s00432-025-06131-y","DOIUrl":"10.1007/s00432-025-06131-y","url":null,"abstract":"<p><strong>Purpose: </strong>CONVINCE is a retrospective medical chart review study that examined demographics, treatment patterns, and outcomes in patients who received first-line (1L) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC) in Germany.</p><p><strong>Methods: </strong>Eligible patients were adults with confirmed la/mUC who received any systemic 1L anticancer treatment between January 1, 2019, and September 30, 2021, outside of a clinical trial. Patients were grouped by type of 1L treatment: platinum-based chemotherapy (PBC), immune checkpoint inhibitor (ICI), or other treatments. Follow-up was ≥ 6 months after end of PBC or start of ICI or other treatments. The primary objective was measurement of real-world progression-free survival (rwPFS).</p><p><strong>Results: </strong>Data were collected from 188 patients treated at 27 sites (hospitals or office-based practices). First-line treatment was PBC in 76.1% of patients, ICI in 19.1%, and other treatments in 4.8%. The most common PBC regimen was cisplatin + gemcitabine (72.7%), and the most common ICI was atezolizumab (44.4%); 4.2% of PBC-treated patients received avelumab 1L maintenance. In patients who received 1L PBC, ICI treatment, or other treatments, median (95% CI) rwPFS was 10.5 months (9.2-11.6), 12.6 months (8.9-22.9), and not evaluable; median (95% CI) real-world overall survival was 18.1 months (16.5-19.0), 15.9 months (11.1-24.5), and not evaluable; and objective response rates were 56.6%, 60.0%, and 83.3%, including complete response in 14.0%, 20.0%, and 0%, respectively.</p><p><strong>Conclusion: </strong>PBC was the most common 1L treatment in patients with la/mUC in Germany, consistent with treatment guidelines. Future studies are needed to assess outcomes with newer treatments.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"100"},"PeriodicalIF":2.7,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882626/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143557007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term results of locoregionally advanced nasopharyngeal carcinoma treated with cisplatin and 5-fluorouracil induction chemotherapy with or without docetaxel in young and middle aged adults.","authors":"Yuming Zheng, Fen Xue, Dan Ou, Xiaoshuang Niu, Chaosu Hu, Xiayun He","doi":"10.1007/s00432-025-06145-6","DOIUrl":"10.1007/s00432-025-06145-6","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to evaluate the efficacy and toxicity of the two induction chemotherapy (IC) regimens (TPF: docetaxel, cisplatin and 5-fluorouracil, and PF: cisplatin and 5-fluorouracil) combined with radiotherapy in young and middle aged patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC).</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 329 cases with stage III-IVA nasopharyngeal carcinoma from September 2005 to February 2017. Of the 329 cases, 253 cases underwent TPF (docetaxel: 60 mg/m² on day 1, cisplatin: 25 mg/m² on days 1-3, 5-fluorouracil: 500 mg/m² on days 1-5, intravenous 120-h infusion), while 76 cases received the PF regimen (cisplatin: 25 mg/m² on days 1-3, 5-fluorouracil: 500 mg/m² on days 1-5, intravenous 120-h infusion) every 3 weeks. Radiotherapy was administered after IC with or without concurrent chemotherapy. The survival rates were assessed by Kaplan-Meier analysis, and the survival curves were compared using a log‑rank test.</p><p><strong>Results: </strong>The 5-year and 8-year overall survival (OS) rates of the PF group and TPF group were 80.1% and 72.1%, 87.3% and 78.4% respectively (p = 0.405). There were no statistical differences in regional recurrence-free survival (RRFS) and distant metastasis-free survival (DMFS) rates between PF and TPF groups(p = 0.585 and 0.500, respectively).The 5-year and 8-year estimated local recurrence free survival (LRFS) rates for patients in PF and TPF group were 91.1% and 78.0%, 96.2% and 93.7%, respectively (p = 0.026). Moreover, The OS, LRFS, RRFS and DMFS rates were comparable between the non CCRT or CCRT subgroup (p = 0.542, 0.319, 0.070, 0.986, respectively). Compared with PF group, the TPF group significantly increased the occurrence of grade 3 or 4 neutropenia and leukopenia (p < 0.001).</p><p><strong>Conclusion: </strong>PF and TPF followed by radiotherapy with or without concurrent chemotherapy performed encouraging anti-tumor effects in LA-NPC, there was no statistical significance in 5-year and 8-year OS, RRFS, and DMFS rates between two chemotherapy regimens. Compared with PF, TPF induction chemotherapy achieved more satisfactory LRFS rate in LA-NPC with acceptable toxicity.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"99"},"PeriodicalIF":2.7,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11880137/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143542081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LncRNA LINC01128 promotes prostate cancer cell proliferation, metastasis, and epithelial-mesenchymal transition by modulating miR-27b-3p.","authors":"Yuhui Zhao, Zhihang Zhang, Yi Zheng, Huiming Bai, Xiaotong Wu, Yantao Yang, Junfeng Zhang, Chao Yu","doi":"10.1007/s00432-025-06153-6","DOIUrl":"10.1007/s00432-025-06153-6","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer (PCa) is a prevalent malignancy within the male reproductive system that poses a significant threat to patients' lives. The function of long non-coding RNA LINC01128 in PCa progression remains to be elucidated.</p><p><strong>Objective: </strong>The objective was to evaluate the significance of LINC01128 in PCa and to elucidate the underlying mechanisms, thereby identifying a potential target for PCa treatment.</p><p><strong>Methods: </strong>The clinical significance of LINC01128 in PCa was investigated by bioinformatics methods and data analysis. The expression of LINC01128 was quantified using real-time quantitative PCR. The impact of LINC01128 on PCa cell viability and metastasis was evaluated through Cell Counting Kit-8 and Transwell assays. The expression of epithelial-mesenchymal transition markers was analyzed by Western blot analysis. Bioinformatics methods and dual-luciferase reporter assay were employed to explore the mechanisms underlying the role of LINC01128 in PCa progression.</p><p><strong>Results: </strong>LINC01128 demonstrated significant upregulation in PCa and exhibited a strong correlation with tumor-node-metastasis (TNM) stage, Gleason score, and lymph node metastasis. The upregulation of LINC01128 was found to be linked to a poorer prognosis for PCa. In PCa cells, silencing LINC01128 resulted in the suppression of cell proliferation, migration, and invasion. Furthermore, the knockdown of LINC01128 enhanced the expression of E-cadherin while concurrently repressing the expression of N-cadherin and Vimentin. Mechanistically, the negative regulation of miR-27b-3p by LINC01128 mediated the role of LINC01128 in PCa progression.</p><p><strong>Conclusions: </strong>In PCa, high expression of LINC01128 may predict patients' unfavorable prognosis. LINC01128 promoted PCa cellular processes by negatively regulating miR-27b-3p.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"98"},"PeriodicalIF":2.7,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11880183/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143542077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}